# Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

> **NCT03117335** · PHASE3 · COMPLETED · sponsor: **Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.** · enrollment: 560 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Placebos
- **DRUG:** Sulijia

## Key facts

- **NCT ID:** NCT03117335
- **Lead sponsor:** Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-10
- **Primary completion:** 2016-11-14
- **Final completion:** 2017-01-17
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117335, "Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03117335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*